A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women

NCT00630539 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Atrophy
Vaginal Diseases

Interventions

DRUG: Placebo
DRUG: Ospemifene 5 mg
DRUG: Ospemifene 15 mg
DRUG: Ospemifene 30 mg

Sponsor

Shionogi

Collaborators

[object Object]
[object Object]